title: Choosing the best treatment for esophageal cancer : criteria for selecting the best multimodal therapy.
abstract: The best multimodal therapy in esophageal cancer comprises neoadjuvant radiochemotherapy in patients with adenocarcinoma or squamous cell carcinoma whereas neoadjuvant chemotherapy is only appropriate for patients with adenocarcinoma. However, the 2-year survival benefit by this induction therapy compared to surgery alone is only 5-9 %. Targeted drugs seem to be promising in order to improve the response rate. The choice of the best multimodal therapy by response prediction seems only to be possible in patients during chemotherapy for adenocarcinoma, whereas during neoadjuvant radiochemotherapy a response prediction by FDG-PET is not possible. The principle item of multimodal therapy is still transthoracic en bloc esophagectomy which should be performed in high volume centers in order to guarantee stable and good results.
authors.affiliation: Department of General, Visceral and Cancer Surgery, University of Cologne, Köln, Germany. Arnulf.Hoelscher@uk-koeln.de
authors.forename: A H
authors.initials: AH
authors.lastname: Hölscher
authors.forename: E
authors.initials: E
authors.lastname: Bollschweiler
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D004938:Esophageal Neoplasms / Q000628:therapy*; D016629:Esophagectomy; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*